Motor cortex dysfunction revealed by cortical excitability studies in Parkinson's disease: influence of antiparkinsonian treatment and cortical stimulation
- PMID: 15661100
- DOI: 10.1016/j.clinph.2004.11.017
Motor cortex dysfunction revealed by cortical excitability studies in Parkinson's disease: influence of antiparkinsonian treatment and cortical stimulation
Abstract
Single or paired pulse paradigms of transcranial magnetic stimulation (TMS) provide several parameters to test motor cortex excitability, such as motor threshold (MT), motor evoked potential (MEP) amplitude, electromyographic silent period to cortical stimulation (CSP) and intracortical facilitation (ICF) or inhibition (ICI). Various changes in TMS parameters, revealing motor cortex dysfunction, were found in patients with Parkinson's disease (PD). For instance, low MT and increased MEP size disclosed an enhanced corticospinal motor output at rest, while reduced ICF and failure of MEP size increase during contraction suggested defective facilitatory cortical inputs, particularly for movement execution. Inhibitory cortical pathways were also found less excitable at rest (reduced ICI) and sometimes during contraction (shortened CSP). By restoring cortical inhibition, dopaminergic drugs and deep brain stimulation probably overcome the difficulty to focus neuronal activity onto the appropriate network required for a specific motor task. The application of repetitive TMS trains over motor cortical areas also showed some effect on cortical excitability, opening perspectives to consider the motor cortex as a target for therapeutic neuromodulation in PD. However, systematic studies of cortical excitability remained to be performed in large series of patients with PD, taking into account disease stage, clinical symptoms and medication influence.
Similar articles
-
Improvement of motor performance and modulation of cortical excitability by repetitive transcranial magnetic stimulation of the motor cortex in Parkinson's disease.Clin Neurophysiol. 2004 Nov;115(11):2530-41. doi: 10.1016/j.clinph.2004.05.025. Clin Neurophysiol. 2004. PMID: 15465443 Clinical Trial.
-
Effects of DBS, premotor rTMS, and levodopa on motor function and silent period in advanced Parkinson's disease.Mov Disord. 2009 Apr 15;24(5):672-6. doi: 10.1002/mds.22417. Mov Disord. 2009. PMID: 19185021 Clinical Trial.
-
Asymmetric corticomotor excitability correlations in early Parkinson's disease.Mov Disord. 2007 Aug 15;22(11):1587-93. doi: 10.1002/mds.21565. Mov Disord. 2007. PMID: 17523196
-
Repetitive transcranial magnetic stimulation (rTMS): insights into the treatment of Parkinson's disease by cortical stimulation.Neurophysiol Clin. 2006 May-Jun;36(3):125-33. doi: 10.1016/j.neucli.2006.08.003. Epub 2006 Aug 22. Neurophysiol Clin. 2006. PMID: 17046607 Review.
-
Repetitive transcranial magnetic stimulation to improve mood and motor function in Parkinson's disease.J Neurol Sci. 2006 Oct 25;248(1-2):84-96. doi: 10.1016/j.jns.2006.05.009. Epub 2006 Jun 21. J Neurol Sci. 2006. PMID: 16793065 Review.
Cited by
-
Cerebellar repetitive transcranial magnetic stimulation has no effect on contraction-induced facilitation of corticospinal excitability.PLoS One. 2024 Nov 1;19(11):e0310173. doi: 10.1371/journal.pone.0310173. eCollection 2024. PLoS One. 2024. PMID: 39485742 Free PMC article.
-
Functional Connectivity Changes of Key Regions for Motor Initiation in Parkinson's Disease.Cereb Cortex. 2019 Jan 1;29(1):383-396. doi: 10.1093/cercor/bhy259. Cereb Cortex. 2019. PMID: 30418548 Free PMC article.
-
Individual Differences in Resting Corticospinal Excitability Are Correlated with Reaction Time and GABA Content in Motor Cortex.J Neurosci. 2017 Mar 8;37(10):2686-2696. doi: 10.1523/JNEUROSCI.3129-16.2017. Epub 2017 Feb 8. J Neurosci. 2017. PMID: 28179557 Free PMC article.
-
Longitudinal dynamics of clinical and neurophysiological changes in parkinson's disease over four and a half years.Sci Rep. 2025 Jul 26;15(1):27284. doi: 10.1038/s41598-025-13558-3. Sci Rep. 2025. PMID: 40715548 Free PMC article.
-
Brain Effects of SC-Nanophytosomes on a Rotenone-Induced Rat Model of Parkinson's Disease-A Proof of Concept for a Mitochondria-Targeted Therapy.Int J Mol Sci. 2022 Oct 21;23(20):12699. doi: 10.3390/ijms232012699. Int J Mol Sci. 2022. PMID: 36293562 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical